South Korea Ophthalmic Topical Therapeutics Market

ID: MRFR/HC/50784-HCR
200 Pages
Nidhi Mandole
Last Updated: March 02, 2026
South Korea Ophthalmic Topical Therapeutics Market Research Report By Product Type (Artificial Tears, Anti-allergy, Antibiotic Drops, Anti-Inflammatory, Antiglaucoma, Others), By Disease Type (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Others), By Dosage Form (Eye Drops, Gels, Ointments, Others) and By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035
South Korea Ophthalmic Topical Therapeutics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.25%
2024 Market Size$ 473.31 Million
2025 Market Size$ 507.62 Million
2035 Market Size$ 1,022.34 Million
Key Players
Allergan
Novartis
Bausch Health
Santen Pharmaceutical
Regeneron Pharmaceuticals
Hoya Corporation
Trends
  • Rising Incidence of Eye Disorders
  • Technological Advancements in Drug Delivery
  • Regulatory Support for New Therapies
Opportunities
  • Increasing Aging Population
  • Rising Healthcare Expenditure
  • Growing Awareness of Eye Health
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Product Type (USD Million)
      1. 4.1.1 Artificial Tears
      2. 4.1.2 Anti-allergy
      3. 4.1.3 Antibiotic Drops
      4. 4.1.4 Anti-inflammatory
      5. 4.1.5 Antiglaucoma
      6. 4.1.6 Others
    2. 4.2 Pharmaceutical, BY Disease Type (USD Million)
      1. 4.2.1 Dry Eye
      2. 4.2.2 Eye Allergy
      3. 4.2.3 Glaucoma
      4. 4.2.4 Eye Infection
      5. 4.2.5 Retinal Disorders
      6. 4.2.6 Uveitis
      7. 4.2.7 Others
    3. 4.3 Pharmaceutical, BY Dosage Form (USD Million)
      1. 4.3.1 Eye Drops
      2. 4.3.2 Gels
      3. 4.3.3 Ointments
      4. 4.3.4 Others
    4. 4.4 Pharmaceutical, BY Distribution Channel (USD Million)
      1. 4.4.1 Hospital Pharmacies
      2. 4.4.2 Drug Stores
      3. 4.4.3 Online Pharmacies
      4. 4.4.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Allergan (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bausch Health (CA)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Santen Pharmaceutical (JP)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Regeneron Pharmaceuticals (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Hoya Corporation (JP)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
    3. 6.3 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
    4. 6.4 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
    5. 6.5 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY DISEASE TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY DOSAGE FORM, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY DOSAGE FORM, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY DOSAGE FORM, 2025-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South Korea South Korea Ophthalmic Topical Therapeutics Market Segmentation

South Korea Ophthalmic Topical Therapeutics Market By Product Type (USD Million, 2025-2035)

  • Artificial Tears
  • Anti-allergy
  • Antibiotic Drops
  • Anti-inflammatory
  • Antiglaucoma
  • Others

South Korea Ophthalmic Topical Therapeutics Market By Disease Type (USD Million, 2025-2035)

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Eye Infection
  • Retinal Disorders
  • Uveitis
  • Others

South Korea Ophthalmic Topical Therapeutics Market By Dosage Form (USD Million, 2025-2035)

  • Eye Drops
  • Gels
  • Ointments
  • Others

South Korea Ophthalmic Topical Therapeutics Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.